Compare OPAL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | ENTX |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 62.6M |
| IPO Year | 2021 | 2015 |
| Metric | OPAL | ENTX |
|---|---|---|
| Price | $2.39 | $1.13 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $2.72 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 156.7K | 153.1K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 650.00 | N/A |
| EPS | 0.15 | ★ 0.25 |
| Revenue | ★ $348,975,000.00 | $42,000.00 |
| Revenue This Year | $12.84 | N/A |
| Revenue Next Year | $9.11 | N/A |
| P/E Ratio | $16.17 | ★ $4.75 |
| Revenue Growth | ★ 16.34 | N/A |
| 52 Week Low | $1.65 | $0.91 |
| 52 Week High | $4.08 | $3.22 |
| Indicator | OPAL | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 44.54 |
| Support Level | $2.03 | $0.96 |
| Resistance Level | $2.50 | $1.61 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.41 | 12.50 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.